Search Result

Results for "

TLR7 agonist

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Toll-like Receptor (TLR) (122) ADC Linker (1) ADC Payload (3) Aldehyde Oxidase (AO) (1) Apoptosis (4) Autophagy (10) Drug Derivative (1) Drug Intermediate (1) Drug-Linker Conjugates for ADC (8) EGFR (2) ERK (1) HBV (4) HCV (7) HIV (3) HSV (10) IFNAR (7) IKK (1) Influenza Virus (3) Interleukin Related (8) Isotope-Labeled Compounds (3) Liposome (1) MAPKAPK2 (MK2) (1) MyD88 (1) NF-κB (2) NO Synthase (1) NOD-like Receptor (NLR) (1) Nucleoside Antimetabolite/Analog (5) p38 MAPK (1) PD-1/PD-L1 (2) PROTACs (1) Reactive Oxygen Species (ROS) (3) Reference Standards (12) SARS-CoV (12) TNF Receptor (8)
By Research Areas:	Cancer (78) Infection (29) Inflammation/Immunology (84) Neurological Disease (4)
Click Chemistry:	Azide (2) Alkynes (1)
Oligonucleotides:	Cationic Lipids (1) Adjuvant (1)

136

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

GMP Molecules

Targets Recommended: Toll-like Receptor (TLR)

Cat. No.	상품명	Target	연구분야	Chemical Structure

HY-13740

Resiquimod Maximum Cited Publications 110 Publications Verification R848; S28463	Toll-like Receptor (TLR) HCV	Inflammation/Immunology Cancer
Resiquimod is a Toll-like receptor 7 and 8 (TLR7/TLR8) agonist that induces the upregulation of cytokines such as TNF-α, IL-6 and IFN-α.

HY-103698A

TLR7/8 agonist 1 dihydrochloride 1 Publications Verification	Toll-like Receptor (TLR)	Inflammation/Immunology
TLR7/8 agonist 1 dihydrochloride is a toll-like receptor *TLR7/TLR8* dual-agonistic imidazoquinoline .

HY-103697

Gardiquimod	Toll-like Receptor (TLR)	Cancer
Gardiquimod is an imidazoline TLR7/8 agonist. Gardiquimod inhibits HIV-1 infection of macrophages and activated peripheral blood mononuclear cells (PBMCs). Gardiquimod specifically activates TLR7 at concentrations below 10 μM.

HY-111358

TLR7 agonist 1	Toll-like Receptor (TLR)	Inflammation/Immunology
TLR7 agonist 1 is a selective *TLR7* agonist with an LEC value of 90 nM. TLR7 agonist 1 activates downstream immune regulation and shows no activity against *TLR8. TLR7* agonist 1 induces endogenous IFN-α production in mice .

HY-117602

TLR7 agonist 3 1 Publications Verification	Toll-like Receptor (TLR)	Neurological Disease Inflammation/Immunology Cancer
TLR7 agonist 3 (compound 2) is a *TLR7* agonist and can be used for the stuy of cancers .

HY-103039

TLR7 agonist 2 1 Publications Verification	Toll-like Receptor (TLR)	Inflammation/Immunology
TLR7 agonist 2 is a potent and selective Toll-like Receptor 7 (TLR7) agonist with a LEC of 0.4 μM.

HY-103698

TLR7/8 agonist 1 1 Publications Verification	Toll-like Receptor (TLR)	Inflammation/Immunology
TLR7/8 agonist 1 is a toll-like receptor (TLR7)/TLR8 dual-agonistic imidazoquinoline.

HY-115400

1V209 4 Publications Verification TLR7 agonist T7	Toll-like Receptor (TLR)	Cancer
1V209 (TLR7 agonist T7) is a Toll-like receptor 7 (TLR7) agonist and has anti-tumor effects. 1V209 can be conjugated with various polysaccharides to improve its water solubility, and enhance its efficacy, and maintain low toxicity .

HY-15601

Vesatolimod 10+ Cited Publications GS-9620	Toll-like Receptor (TLR) Apoptosis HBV HCV HIV	Inflammation/Immunology
Vesatolimod (GS-9620) is a potent, selective and orally active agonist of Toll-Like Receptor (TLR7) with an EC₅₀ of 291 nM.

HY-109104

Telratolimod 5+ Cited Publications MEDI9197; 3M-052	Toll-like Receptor (TLR)	Cancer
Telratolimod (MEDI9197) is a potent toll like receptors 7/8 (TLR7/8) agonist, with antitumor activity .

HY-128799

CL097 2 Publications Verification	Toll-like Receptor (TLR) Reactive Oxygen Species (ROS)	Inflammation/Immunology
CL097, a potent *TLR7* and *TLR8* agonist, induces pro-inflammatory cytokines in macrophages . CL097 induces NADPH oxidase priming, resulting in an increase of the fMLF-stimulated ROS production .

HY-139017

TLR7/8 agonist 4	Toll-like Receptor (TLR)	Neurological Disease Inflammation/Immunology Cancer
TLR7/8 agonist 4 (compound 41) is a potent *TLR7/8* agonist. TLR7/8 agonist 4 has anti-cancer activity .

HY-145961

TLR7 agonist 4	Toll-like Receptor (TLR) TNF Receptor	Cancer
TLR7 agonist 4 is a *TLR7* agonist with pro-inflammatory cytokine-stimulating activity. TLR7 agonist 4 modulates *TLR7* activity to stimulate the production of pro-inflammatory cytokines. TLR7 agonist 4 stimulates mouse bone marrow-derived macrophages to produce the pro-inflammatory cytokine TNFα. TLR7 agonist 4 can be conjugated with antibodies to form conjugates. TLR7 agonist 4 is applicable to cancer research .

HY-145885

TLR7/8 agonist 6	Toll-like Receptor (TLR) TNF Receptor Interleukin Related IFNAR	Infection Inflammation/Immunology Cancer
TLR7/8 agonist 6 is a *TLR7/8* agonist with EC₅₀s of 0.18 μM and 5.34 μM in TLR7 or TLR8 HEK-SEAP reporter cells, respectively. TLR7/8 agonist 6 potently stimulates production of TNFα, IFNγ, and IL-1β. TLR7/8 agonist 6 can be used for research on cancer and infectious diseases .

HY-111582

BBIQ	Toll-like Receptor (TLR)	Inflammation/Immunology
BBIQ is a imidazoquinoline compound and a potent and selectively toll-like receptor 7 (TLR7) agonist with an EC₅₀ of 59.1 nM for human TLR7. BBIQ is a powerful vaccine adjuvant that enhances innate immune responses .

HY-164485

INI-4001	Toll-like Receptor (TLR) SARS-CoV	Infection
INI-4001 is a *TLR7/8* agonist and vaccine adjuvant. INI-4001 regulates innate and adaptive immune responses by activating murine *TLR7* and human *TLR7/TLR8. INI-4001 enhances IgG and neutralizing antibody responses against Powassan virus (POWV), reduces viral loads in the brain, liver and spleen, provides complete protection against lethal POWV challenge, and skews immune responses toward a Th1* phenotype. When INI-4001 is used in combination with Al (OH)₃ and SARS-CoV-2 RBD antigen, it efficiently adsorbs to Al (OH)₃, promotes Th1 immunity and enhances SARS-CoV-2 neutralizing antibody responses. INI-4001 is applicable to research related to Powassan virus infection and COVID-19 .

HY-138139A

AXC-715 hydrochloride T785 hydrochloride	Toll-like Receptor (TLR)	Inflammation/Immunology Cancer
AXC-715 (T785) hydrochloride is a *TLR7/TLR8* dual agonist. AXC-715 can be used for synthesis of antibody-adjuvant immunoconjugates, comprising an antibody construct that binds programmed death-ligand 1 (PD-L1) linked to one or more adjuvants .

HY-130797

TLR7/8 agonist 3	Toll-like Receptor (TLR)	Cancer
TLR7/8 agonist 3 (Compound II) is a potent *TLR7* and *TLR8* agonist, extracted from patent WO2016057618 (compound of formula (II)) .

HY-139018A

TLR7/8 agonist 4 hydroxy-PEG10-acid hydrochloride	Drug-Linker Conjugates for ADC	Cancer
TLR7/8 agonist 4 hydroxy-PEG10-acid hydrochloride (compound 9) is a drug-linker conjugates for ADC with potent antitumor activity by using TLR7/8 agonist 4 (HY-139018; a TLR7/8 agonist), linked via the non-cleavable ADC linker hydroxy-PEG10-acid (HY-133307) .

HY-110120

DSR-6434 1 Publications Verification	Toll-like Receptor (TLR)	Cancer
DSR-6434 is a potent and selective Toll-like receptor 7 (TLR7) agonist, with EC₅₀s of 7.2 nM and 4.6 nM for human and mice *TLR7*, respectively. DSR-6434 has a strong antitumor effect .

HY-111269

AZD8848 1 Publications Verification	Toll-like Receptor (TLR)	Inflammation/Immunology
AZD8848 is a selective toll-like receptor 7 (TLR7) anteagent agonist which is developed for the research of asthma and allergic rhinitis .

HY-153073

TLR7 agonist 8	Toll-like Receptor (TLR) Interleukin Related	Infection Inflammation/Immunology Cancer
TLR7 agonist 8 is a *TLR7* agonist with an EC₅₀ of 0.12 nM for TLR7 and an EC₅₀ of 0.76 nM for IL-6 induction. TLR7 agonist 8 can be used for research on diseases such as fibrosis, inflammatory diseases, cancer, or pathogen infections .

HY-153070

TLR7 agonist 5	Toll-like Receptor (TLR)	Inflammation/Immunology
TLR7 agonist 5 (compound IIb-11) is an *TLR7* agonist with an EC₅₀ value of ~4 nM .

HY-158694A

TLR7 agonist 20 hydrochloride	Toll-like Receptor (TLR)	Inflammation/Immunology
TLR7 agonist 20 hydrochloride is a selective Toll-like receptor 7 (TLR7) agonist with an EC₅₀ of 0.22 μM. TLR7 agonist 20 hydrochloride, as an immunostimulant and vaccine adjuvant, enhances the production of anti-spike protein antibodies, increases IgG2b and IgG2c levels, and thereby drives Th1-type immune responses in mice. TLR7 agonist 20 hydrochloride can be used in studies related to non-inflammatory potent vaccine adjuvants .

HY-144619

TLR7/8 antagonist 2	Toll-like Receptor (TLR)	Inflammation/Immunology
TLR7/8 antagonist 2 (Compound 15) is a potent and orally active agonist of *TLR7/8* with IC₅₀s of 4.9 and 0.6 nM, respectively. Inappropriate activation of TLR7 and TLR8 is linked to several autoimmune diseases, such as lupus erythematosus. TLR7/8 antagonist 2 has the potential for the research of autoimmune diseases .

HY-135905

CL264	Toll-like Receptor (TLR)	Inflammation/Immunology
CL264 is a *TLR7*-specific agonist for innate immune signals research .

HY-139018

TLR7/8 agonist 4 hydroxy-PEG10-acid	Drug-Linker Conjugates for ADC	Cancer
TLR7/8 agonist 4 hydroxy-PEG10-acid (compound 9) is a drug-linker conjugates for ADC with potent antitumor activity by using TLR7/8 agonist 4 (HY-139018; a TLR7/8 agonist), linked via the non-cleavable ADC linker hydroxy-PEG10-acid (HY-133307) .

HY-103697A

Gardiquimod diTFA	Toll-like Receptor (TLR)	Cancer
Gardiquimod diTFA is an imidazoline TLR7/8 agonist. Gardiquimod diTFA inhibits HIV-1 infection of macrophages and activated peripheral blood mononuclear cells (PBMCs). Gardiquimod diTFA specifically activates TLR7 at concentrations below 10 μM.

HY-156174

E104	Toll-like Receptor (TLR) ADC Payload	Cancer
E104 (compound 1) is a potent and selective *TLR7* agonist. E104 can be delivered by antibody-drug conjugate (ADC) technology to elicit potent anticancer activity. E104 induces the activation of mouse macrophages and hPBMCs .

HY-173070

TLR7 agonist 29	Toll-like Receptor (TLR) IFNAR PD-1/PD-L1 ADC Payload	Inflammation/Immunology Cancer
TLR7 agonist 29 (Compound 1) is the agonist for *TLR7* with an EC₅₀ of 5.2 nM for human TLR7 (EC₅₀ for mouse TLR7 is 48.2 nM). TLR7 agonist 29 activates bone marrow-derived macrophages (BMDMs), stimulates myeloid cells in the tumor microenvironment, promotes the expression of PD-L1, CD86 and IFN-α. TLR7 agonist 29 can be used as payload for synthesis of ADC .

HY-153071

TLR7 agonist 6	Toll-like Receptor (TLR)	Inflammation/Immunology
TLR7 agonist 6 (compound IIb-19) is an *TLR7* agonist with an EC₅₀ value of 1.0 nM .

HY-156693A

MTvkPABC-P5 TFA	Toll-like Receptor (TLR)	Inflammation/Immunology
MTvkPABC-P5d TFA, a *TLR7* agonist, is an immune stimulant. MTvkPABC-P5d TFA can be used for synthesis of immune-stimulating antibody conjugates (ISACs) .

HY-163398

TLR7-IN-1	Toll-like Receptor (TLR)	Cancer
TLR7-IN-1 (Compound 16-A) is a *TLR7* agonist with an EC₅₀ of 0.001 μM. TLR7-IN-1 is applicable to cancer-related research .

HY-168159

TLR7 agonist 27	Toll-like Receptor (TLR) NOD-like Receptor (NLR)	Inflammation/Immunology
TLR7 agonist 27 (compound 24) is a potent TLR7 agonist with an EC₅₀ of 238.1 nM. TLR7 agonist 27 shows weak agonistic activity against NOD2 (nucleotide-binding oligomerization domain 2) (EC₅₀ of 6.2 μM). TLR7 agonist 27 is a potent immunostimulant, and can be used as a vaccine adjuvant and/or immunotherapeutic .

HY-156691A

TLR7/8 agonist 4 hydroxy-PEG6-acid hydrochloride	Drug-Linker Conjugates for ADC	Cancer
TLR7/8 agonist 4 hydroxy-PEG6-acid hydrochloride is a drug-linker conjugates for ADC>. TLR7/8 agonist 4 hydroxy-PEG6-acid hydrochloride is the hydrochloride form of TLR7/8 agonist 4 hydroxy-PEG6-acid. TLR7/8 agonist 4 hydroxy-PEG6-acid consists of TLR7/8 agonist 4 (HY-139017) and a non-cleavable linker Hydroxy-PEG6-acid (HY-133050), and can be used for synthesis of ADCs .

HY-145886

TLR7/8 antagonist 1	Toll-like Receptor (TLR) Interleukin Related	Infection Inflammation/Immunology Cancer
TLR7/8 antagonist 1 (Compound 16c) is a competitive *TLR7/8* antagonist with IC₅₀ values of 3.91 μM and 2.19 μM, respectively. TLR7/8 antagonist 1 reduces agonist-induced production of proinflammatory cytokines, including TNFα, IFNγ and IL-1β .

HY-13740S

Resiquimod-d5 1 Publications Verification R848-d₅; S28463-d₅	Isotope-Labeled Compounds Toll-like Receptor (TLR) HCV	Infection Inflammation/Immunology
Resiquimod-d₅ is deuterium labeled Resiquimod. Resiquimod is a Toll-like receptor 7 and 8 (TLR7/TLR8) agonist that induces the upregulation of cytokines such as TNF-α, IL-6 and IFN-α .

HY-123291

SM-276001	Toll-like Receptor (TLR) IFNAR	Inflammation/Immunology Cancer
SM-276001 is a potent selective *TLR7* agonist that can induce antitumor immune responses. SM-276001 is an orally active interferon (IFN) inducer .

HY-128799A

CL097 hydrochloride 2 Publications Verification	Toll-like Receptor (TLR) Reactive Oxygen Species (ROS)	Inflammation/Immunology
CL097, a potent *TLR7* and *TLR8* agonist, induces pro-inflammatory cytokines in macrophages . CL097 induces NADPH oxidase priming, resulting in an increase of the fMLF-stimulated ROS production .

HY-179007

TLR7 agonist 31	Toll-like Receptor (TLR)	Cancer
TLR7 agonist 31 (Compound 116) is a *TLR7* agonist, with an EC₅₀ of 31 nM. TLR7 agonist 31 can be used in the research of cancer .

HY-179275

TLR7 agonist 33	Toll-like Receptor (TLR)	Cancer
TLR7 agonist 33 (Compound 141) is a potent *TLR7* activator with an EC₅₀ of 1 nM. TLR7 agonist 33 can be used for cancer research .

HY-173079

TLR7 agonist 30	Toll-like Receptor (TLR) Drug-Linker Conjugates for ADC	Cancer
TLR7 agonist 30 (compound 2) is an agent-linker conjugate for ADC. TLR7 agonist 30 contains a TLR7 agonist (compound 1) and a cleavable linker, and has potent anti-tumor activity .

HY-156177

TLR7 agonist 16	Toll-like Receptor (TLR)	Inflammation/Immunology
TLR7 agonist 16 (compound 16d) is a highly potent *TLR7* agonist with an EC₅₀ of 18 nM. TLR7 agonist 16 potently induces the activation of mouse macrophages and hPBMCs at low-nanomolar concentrations .

HY-156176

TLR7 agonist 15	Toll-like Receptor (TLR)	Inflammation/Immunology
TLR7 agonist 15 (compound 16b) is a highly potent *TLR7* agonist with an EC₅₀ of 18 nM. TLR7 agonist 15 potently induces the activation of mouse macrophages and hPBMCs at low-nanomolar concentrations .

HY-153072

TLR7 agonist 7	Toll-like Receptor (TLR)	Inflammation/Immunology
TLR7 agonist 7 (compound IIb-26) is an *TLR7* agonist with an EC₅₀ value of ~4 nM .

HY-152726

TLR7 agonist 9	Toll-like Receptor (TLR) Nucleoside Antimetabolite/Analog	Infection Cancer
TLR7 agonist 9 (compound 10) is an aonist of *TLR7. TLR7* agonist 9 can be used for research of cancer and infectious disease . TLR7 agonist 9 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-176202

TLR7/8 agonist 12-PAB-(PEG4-Me)-Cit-Val-PEG2-amide-C2-MC	Drug-Linker Conjugates for ADC	Cancer
TLR7/8 agonist 12-PAB-(PEG4-Me)-Cit-Val-PEG2-amide-C2-MC (compound LIV1-IMC (12) linker-payload) is a linker-payload conjugate, used in the synthesis of antibody-drug conjugates (ADCs).TLR7/8 agonist 12-PAB-(PEG4-Me)-Cit-Val-PEG2-amide-C2-MC contains TLR7/8 agonist (HY-170770) (ADC payload) and a linker (HY-176478) .

HY-158694

TLR7 agonist 20	Toll-like Receptor (TLR)	Inflammation/Immunology
TLR7 agonist 20 is a selective Toll-like receptor 7 (TLR7) agonist with an EC₅₀ of 0.22 μM. TLR7 agonist 20, as an immunostimulant and vaccine adjuvant, enhances the production of anti-spike protein antibodies, increases IgG2b and IgG2c levels, and thereby drives Th1-type immune responses in mice. TLR7 agonist 20 can be used in studies related to non-inflammatory potent vaccine adjuvants .

HY-179336

TLR7/8 agonist 14	Toll-like Receptor (TLR) Interleukin Related IFNAR TNF Receptor	Cancer
TLR7/8 agonist 14 is a *TLR7* and *TLR8* agonist with EC₅₀ values of 0.53 μM and 4.3 μM, respectively. TLR7/8 agonist 14 increases the secretion of the proinflammatory cytokines TNF-α, IL-1β, IL-8 and IFN-γ. TLR7/8 agonist 14 increases cytokine secretion and expression of CD86. LR7/8 agonist 14 can be used for research colorectal carcinoma .

HY-145960

*MC-Val-Cit-PAB-Amide-TLR7* agonist 4**	EGFR Toll-like Receptor (TLR)	Inflammation/Immunology
MC-Val-Cit-PAB-Amide-TLR7 agonist 4 (example 15) is a *HER2-TLR7* and *HER2-TLR8* immune agonist conjugate .

Cat. No.	상품명	Type

HY-13740G

Resiquimod R848; S28463	Fluorescent Dyes
Resiquimod (R848) (GMP) is Resiquimod (HY-13740) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Resiquimod is a Toll-like receptor 7 and 8 (TLR7/TLR8) agonist. Resiquimod (GMP) can induce human mMDSC to mature into inflammatory macrophages .

HY-111582G

BBIQ (GMP)	Fluorescent Dyes
BBIQ (GMP) is BBIQ (HY-111582) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. BBIQ is a potent and selectively toll-like receptor 7 (TLR7) agonist with an EC₅₀ of  59.1 nM. BBIQ is a powerful vaccine adjuvant that enhances innate immune responses .

Cat. No.	상품명	Type

HY-13740G

Resiquimod R848; S28463	Biochemical Assay Reagents
Resiquimod (R848) (GMP) is Resiquimod (HY-13740) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Resiquimod is a Toll-like receptor 7 and 8 (TLR7/TLR8) agonist. Resiquimod (GMP) can induce human mMDSC to mature into inflammatory macrophages .

HY-111582G

BBIQ (GMP)	Biochemical Assay Reagents
BBIQ (GMP) is BBIQ (HY-111582) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. BBIQ is a potent and selectively toll-like receptor 7 (TLR7) agonist with an EC₅₀ of  59.1 nM. BBIQ is a powerful vaccine adjuvant that enhances innate immune responses .

Cat. No.	상품명	Chemical Structure

HY-13740S

Resiquimod-d5 1 Publications Verification
Resiquimod-d₅ is deuterium labeled Resiquimod. Resiquimod is a Toll-like receptor 7 and 8 (TLR7/TLR8) agonist that induces the upregulation of cytokines such as TNF-α, IL-6 and IFN-α .

HY-B0180S1

Imiquimod-d9
Imiquimod-d₉ is deuterium labeled Imiquimod. Imiquimod (R 837), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19 .

HY-B0180S

Imiquimod-d6
Imiquimod-d₆ is the deuterium labeled Imiquimod. Imiquimod (R 837), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19 .

HY-B0180S2

Imiquimod-d7
Imiquimod-d₇ (R 837-d₇) is deuterium labeled Imiquimod. Imiquimod (R 837), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19 .

Cat. No.	상품명		Classification

HY-159102

PVP-037.2		Azide
PVP-037.2 is a *TLR7/8* agonist. PVP-037.2 can serve as an adjuvant to enhance vaccine-induced T_H1 type immune responses, increasing the production of antigen-specific antibodies IgG1 and IgG2c .

HY-154361

TLR7 agonist 13		Alkynes
TLR7 agonist 13 is a guanosine analog. Some guanosine analogs have immunostimulatory activity. In some animal models, they also induce type I interferons, producing antiviral effects. Studies have shown that the functional activity of guanosine analogs is dependent on the activation of Toll-like receptor 7 (TLR7) . TLR7 agonist 13 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-159100

PVP-037		Azide
PVP-037 is a potent *TLR7* and *TLR8* agonist adjuvant. PVP-037 shows broad innate immune activation and enhances vaccine immune responses .

Cat. No.	상품명		Classification

HY-111582

BBIQ		Adjuvant
BBIQ is a imidazoquinoline compound and a potent and selectively toll-like receptor 7 (TLR7) agonist with an EC₅₀ of 59.1 nM for human TLR7. BBIQ is a powerful vaccine adjuvant that enhances innate immune responses .

HY-169478

Lipid N2-3L		Cationic Lipids
Lipid N2-3L is an ionizable cationic lipid (pK_a = 8.99) that can be used to generate supramolecular lipid nanoparticles (SMLNPs) for mRNA delivery. Lipid nanoparticles formed by encapsulating a luciferase reporter gene with Lipid N2-3L were detected to accumulate in the lymph nodes of mice, indicating that they can effectively enter the mouse immune system. Lipid nanoparticles formed by encapsulating ovalbumin mRNA and the TLR7/8 agonist Resiquimod (HY-13740) with Lipid N2-3L were able to reduce tumor volume and increase survival in the MC-38-OVA mouse colon cancer model. Lipid N2-3L can be used in the research of drug delivery for cancer-related therapies .

Targets Recommended: Toll-like Receptor (TLR)

Cat. No.	상품명	Target	연구분야	Chemical Structure

HY-13740G

Resiquimod R848; S28463	Toll-like Receptor (TLR)	Inflammation/Immunology Cancer
Resiquimod (R848) (GMP) is Resiquimod (HY-13740) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Resiquimod is a Toll-like receptor 7 and 8 (TLR7/TLR8) agonist. Resiquimod (GMP) can induce human mMDSC to mature into inflammatory macrophages .

온라인 문의

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
호칭			Country or Region *
고객명 *			회사명 *
Department *
메일주소 *			상품명 *
Cat. No.			Requested quantity *
전화번호 *
비고

온라인 문의

Inquiry Information

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent: